pharma · Metastatic Colorectal Cancer · Duchenne Muscular Dystrophy · SMMT
Summit Therapeutics
NovaPharmaNews editorial coverage mentioning Summit Therapeutics — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 601 Brickell Key Dr, Suite 1000, Miami, Florida 33131, US
- Founded
- 2003
- Employees
- 367
- Programs
- 41
- Drugs
- 32
- Patents
- 20
News & analysis
NovaPharmaNews articles mentioning Summit Therapeutics — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Summit Therapeutics — regulatory, clinical, and market analysis.
ASCO Summit: Ivonescimab's China Lung Data Shows Promise, But Global Validation Remains Key
Summit Therapeutics' ivonescimab demonstrated a significant survival benefit in a Chinese lung cancer trial presented at ASCO, yet analysts caution that replicating these results in a broader, global population is crucial for its market potential against established therapies like Keytruda.
ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study
Structured plan for ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study
Biotech Movers: Moderna, Iovance, ALHC, and Summit Therapeutics in Focus
Biotech stocks showed mixed performance as Moderna advanced its Ebola vaccine efforts and Summit Therapeutics saw a surge on Phase 3 data. Meanwhile, Alignment Healthcare faced a downgrade, and Iovance Biotherapeutics remains a subject of analyst debate.
#ASCO26 Insights: Head and Neck Cancer Developments
This article reviews significant head and neck cancer findings from ASCO26, focusing on insights from J&J, Corbus, Summit, Akero, and Bicara. Discover the implications for pharmaceutical stakeholders.